Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.
I bought 5k @ 21p yest and did not show
If you look at the profile of a copany like Allied Minds / IPO / Imperial they trade on multiples of book value because they can access the tech pipelines of Uni's and in AM's case the DOD... early stage technology = potential value creation. WPCT can fund whatever he likes including the above co's best companies, which could result in a high % of winners in the private space, albeit with lower IRR's than AM/IPO/Imperial because investing at slightly later stage - for example look at the investment into sciflour, an AM company. Will WPCT always trade close to NAV + premium or will it follow AM valuation etc (mutilple of book value because the subsidiaries are potentially disruptive + pipeline has a value)...will no doubt depend how the first 12 months of value creation goes...but for the patient could see some very good returns.
already up 4%
CAMBRIDGE, England, May 6, 2015 /PRNewswire/ -- Woodford Patient Capital Trust plc and Malin Corporation plc join the Wellcome Trust and the Bill & Melinda Gates Foundation to Complete Series B Financing Kymab, a leading monoclonal antibody biopharmaceutical company, announced today that it has successfully raised an additional US$50 million to complete a US$90 million Series B financing. The US$50 million is being invested by Woodford Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation plc (ISE:MLC,"Malin"). This follows the first US$40 million Series B investment from the Wellcome Trust and the Bill & Melinda Gates Foundation. The funds will enable Kymab to maximize the potential of its Kymouse™ platform and advance its proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need. In association with the financing, Kymab has added two pre-eminent life science executives to the Board. G. Kelly Martin, former CEO of Elan Corporation, plc, and Director of Malin; and Dr. Adrian Howd, CEO of Malin. David Chiswell, Chairman and interim CEO of Kymab, said: "We are delighted to welcome high qualityinvestors of the calibre of Malin and Woodford to Kymab which support our goal to build Kymab into a sustainable biopharmaceutical company. The funds will be used to maximise the potential of the Kymab pipeline as we develop and commercialise monoclonal antibody medicines for difficult and novel drug targets." Kelly Martin, Director of Malin, said: "Kymab has assembled a talented leadership team; an efficient and effective discovery platform with broad application demonstrated by the pipeline of product opportunities already established. We look forward to working with David and his team to fully realize the potential of the Company's programs, initially in immune-oncology and immunology, and the broader technology platform." Adrian Howd, CEO of Malin, said: "We believe Kymab has one of the most comprehensive humanised transgenic antibody platforms underpinned by strong intellectual property. We are pleased to invest in a world leading antibody company." Kymab is using the Kymouse™ transgenic human antibody platform to discover and develop fully human monoclonal antibody drugs. Recent data published in Nature Biotechnology demonstrate that the Kymouse™ technology yields an antibody library constituted from 100 trillion different antibodies. From this deep library rare high-quality antibodies can be selected and developed into therapeutics. Antibodies are one of the best-selling classes of drugs today; five of the top ten best selling drugs are antibodies. This is because antibodies are natural products with exquisite specificity and potency, and generally have superior safety profiles. The challenge has been to capture the full human antibody repertoire and to recapitulate a
Allied Minds' Subsidiary SciFluor Life Sciences Raises $30 Million and Names William Koster, PhD, Former CEO of Neurogen Corp., as Chairman · SciFluor's recent advancements in its pipeline, comprised of two lead compounds and additional discovery assets using the strategic incorporation of fluorine to create best-in-class drugs, generated investor interest. · SciFluor's plans to develop fluorine-containing new chemical entities (NCEs) across multiple disease states will benefit from the addition of William Koster, whose accomplishments include success in senior executive roles in small molecule drug discovery and early clinical development at Neurogen Corp. and Bristol-Myers Squibb Co. Boston, MA (April 22, 2015) - Allied Minds (LSE: ALM), an innovative U.S. science and technology development and commercialization company, today announced that its subsidiary company, SciFluor Life Sciences, has raised $30 million. Proceeds will be used to accelerate its two lead compounds - one a topical treatment for retinal diseases and the second a treatment for neurological diseases - while expanding its drug discovery and commercialization pipeline. SciFluor also named William Koster, PhD, a seasoned executive in drug discovery research and early clinical development, as Chairman of the Board. Koster previously served as President and Chief Executive Officer of Neurogen Corp., a NASDAQ-listed biotechnology company engaged in neuroscience R&D. He also spent 30 years with Bristol-Myers Squibb Co. in various roles that included Senior Vice President overseeing worldwide drug discovery research and early clinical development through Phase 2a. SciFluor is focusing its efforts on the strategic use of fluorine to create new drugs with improved potency, selectivity, dosing and metabolic stability across multiple disease states, including retinal disease, CNS disorders, pain, pulmonary and inflammatory disease. The company recently announced the issuance of two U.S. patents for potentially breakthrough lead compounds to treat retinal diseases and epilepsy. Treatments for retinal diseases, such as Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME), represent a more than $6 billion market opportunity, and those for epilepsy and related disorders are estimated at more than $7 billion. "This successful funding round will enable SciFluor to accelerate the development and commercialization of fluorine-enhanced drug therapies," said Omar Amirana, MD, SciFluor's Chief Executive Officer and Senior Vice President at Allied Minds. "We are delighted with the support of our investors and warmly welcome Bill to the Board. His guidance will be tremendously valuable." Significant participants in the funding round are Invesco Asset Management (Invesco), Woodford Investment Management (Woodford) and Allied Minds, SciFluor's parent company. SciFluor's two recent patents in
The market was just expecting their stake to be worth more....whether it was sold beforehand or they kept a stake for the prospect to be drilled. Now agta is back to being a quality slow moving agricultural play which will no doubt do well long term but the "hot" money seems to be moving on.
I sold out this news on the basis I wanted to be in for the drill or for some of the money raised to be distributed as a special dividend. Made about 50%...so lower than my original target.
We know the fund are selling down their holdings as per the rns releases so it could be them. This is just a waiting game for news on the drilling front...price is drifting between news. I think the 2 most likely options will be the stake is sold beforehand and a special divi will be paid or we'll go for the drill and it'll be like any other oiler where we have to cross our fingers and hope. Apart from the fact it isn't because downside is protected by the agri business. Therefore I am aiming for at least a 100% return from this price over the next 1-6 months.
“Promising” oil find in South Omo block By Elias Gebreselassie Wednesday, 12 September 2012 09:58 0 Comments A new report suggests that Africa-focused agriculture firm Agriterra’s legacy oil interests in Ethiopia may hold up to 2.7 billion barrels. The other partner in the venture Canadian based Africa Oil said the figure was a best case, gross unrisked estimate derived from an independent review of the South Omo block in Ethiopia. Agriterra has a 20 per cent stake in South Omo with Africa Oil owning 30 per cent and the London United Kingdom based Tullow Oil 50 per cent. Tullow has already made a discovery on its own block in Kenya, which is located within the same petroleum system as South Omo. Tullow Oil, has also stakes in Uganda where it first found oil in Uganda’s Lake Albert Rift Basin and then extended its exploration to the East African Rift Basins of Kenya and Ethiopia in 2010. While the Vancouver based Africa Oil, has already previously bought exploration areas in Ogaden basin, Kenya and Puntland. These concessions were previously held by Lundin Petroleum, the Swedish petroleum company. Recently the company has successfully accomplished its exploration in Puntland, part of the former Somalia, which is now a peaceful and independent state although it is not internationally recognized. The first well planned for the South Omo Block Sabisa-1, is now targeted to be drilled by the end of 2012, following Tullow’s rig contract negotiations in Ethiopia, which are nearing conclusion, Agriterra added. South Omo is situated within the Tertiary age East African Rift just north of Lake Turkana in neighboring Kenya which itself has recently found promising signs of substantial oil reserves, one of the last great rift basins to be explored in East Africa, said the company. Seismic and gravity data from Africa Oil show robust leads and prospects throughout the South Omo Project area, Agriterra said. Chief executive of Agriterra Andrew Groves added the results combined with successful drilling in the same petroleum system confirmed the high value of the concession. He said he was also “extremely excited about the prospect of the first well being drilled by the end of the year.” He added that with the agricultural and ranching businesses going from strength to strength there is the potential for “a great value uplift” at Agriterra.
You are accusing the company of spreading lies, questioning the backing of the institutions and large holders and think the patents are worthless. Have you read any of the patents? No of course you haven't - you don't even know how any of their equipment works or even anything about the company's business model's for each lob. For example do you realise the money to be made on the atomiser front is through chemical aftersales? I doubt it. Time waster!
As usual you are posting complete garbage
Have a read of the last 12 months rns's - there are 2 plants where customers are paying - one of them, the Marquis plant is a c.110 gallon plant (off the top of my head) and is one of the most efficient ethanol plants in America. They have also ordered a second pdx for another plant and have stated it is now part of their standard operating equipment going forwards (They have further plant(s) in the planning process). The trials to prove it works were done a while back. These are installations whereby it is calculated how much dosh a pdx can save (through reduced energy / enzyme etc usage) /make (through yield improvements etc) the ethanol company...when that is calculated (which is a complex process) a commercial fee agreement is signed. 2 down. 12 more to come...that we know about. FYI these are reoccurring revenues to pdx and as there are no moving parts in the pdx - there are very few maintenance costs.
"The reason for my last post was that PD should by now (if my recollection is right) have completed one or more of their biofuels trials. If that was positive, I would have thought it be splashed all over their news page. Their news page is empty. If the trial has not gone well, I am curious about their cash position." As there are 2 biofuel plants (PEIX and Marquis) which have signed commercial deals with pursuit the above statement must be an attempt to mislead. Both ERS's are operating in optimisation mode which means they are paying 2c per gallon produced. You are correct to point out they have another 12 plants (probably 4/5 of which now have the ers's installed in them) going through the base lining process and awaiting to commence commercialisation. When all 12 are installed that will take volume of ethanol under production to 1 billion gallons and also take Pursuit into profitability. That of course is just the ethanol lob...I hope you come back to discuss your doubts if/when the P&G deal is announced.
get a fair amount between now and christmas. P&G update, ethanol lob progress - more contracts, and installations going commercial, brewing and food lob updates - they are going to trade fairs in Chnia and Germany, first orders possible for the karcher JV - portable backpack units, other industrial licensing deals and further progress with other work. Of course any news from the industrial licensing lob (a commercial deal) would transform the company instantly and propel the share price higher.
Too.....:)